CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Toxin Peptide Antagonist of T-type Calcium Channels for use in Analgesia

Référence

01839-01

Statut des brevets

French patent application FR2940973 filed on January 15th, 2009, entitled «Identification d’une nouvelle toxine antagoniste de canaux calciques de type-T à visée analgésique»

Inventeurs

Emmanuel BOURINET
Pierre ESCOUBAS
Joël NARGEOT
Fabrice MARGER
Michel LAZDUNSKI

Statut commercial

Exclusive or non-exclusive licenses

Laboratoire

Institut de Génomique Fonctionnelle a CNRS–INSERM and University de Montpellier laboratory (UMR 5203), in Montpellier, France.

Description

CONTEXT

Transmission of the pain signal by the nervous system involves neuronal receptors which convert the painful stimulus into an electrical signal. The nociceptive neurons, which react specifically to pain stimuli, possess a unique repertory of ion channels that represent ideal targets for new analgesic drug development. Among them, T-type Calcium channels, and in particular CaV3.2, have been shown to be specifically implicated in nociception.

TECHNICAL DESCRIPTION

The inventors have identified PspTx3, a 28 aa-peptide derived from the venom of a spider Theraphosidae, that efficiently inhibits CaV3.2. Besides, PspTx3 revealed to also efficiently inhibit NaV1.7, a sodium channel implicated in pain conduction and a very interesting target for pain treatment. Using a mouse model of chronic pain induced by sciatic nerve lesion, the peripheral injection of the toxin (subcutaneous injection in the leg) showed a much more potent effect on nociception compared to morphine. No cardiac toxicity could be detected.

INDUSTRIAL APPLICATIONS

Drug development for use in pain treatment.

For further information, please contact us (Ref 01839-01)

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents